Dr. Pankaj Mohan founded Sonnet in 2015 and currently serves as Chief Executive Officer and Chairman. He is also a member of the Board of Directors of Outlook Therapeutics, Inc. which he also founded (formerly known as Oncobiologics). From January 2011 to June 2018, he served as Oncobiologics’ President, Chief Executive Officer, and Chairman. Previously, Dr. Mohan served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company and as a Director of Bioprocess Engineering at Genentech, Inc. Prior to that Dr. Mohan served as a senior manager at Eli Lilly and Company. From May 1993 to April 1996, Dr. Mohan served as Assistant Professor (Lecturer/Fellow) at the Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom.
Dr. Mohan received a Doctor of Philosophy in Biochemical Engineering from the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom, a master’s in financial management from Middlesex University Business School, London, United Kingdom, and a bachelor’s degree in chemical engineering from the Indian Institute of Technology in Roorkee, India. Dr. Mohan also attended an Executive Management Program (AMP) from Fuqua School of Business at Duke University.
What is Pankaj Mohan's net worth?
The estimated net worth of Pankaj Mohan is at least $240,366.99 as of May 15th, 2023. Dr. Mohan owns 553,331 shares of Sonnet BioTherapeutics stock worth more than $240,367 as of June 7th. This net worth approximation does not reflect any other assets that Dr. Mohan may own. Additionally, Dr. Mohan receives an annual salary of $792,170.00 as CEO at Sonnet BioTherapeutics. Learn More about Pankaj Mohan's net worth.
What is Pankaj Mohan's salary?
As the CEO of Sonnet BioTherapeutics Holdings, Inc., Dr. Mohan earned a total compensation package of $792,165.00 in 2021. Dr. Mohan earned a salary of $512,236.00, a bonus of $279,930.00, and no other miscellaneous compensation. Learn More on Pankaj Mohan's salary.
How do I contact Pankaj Mohan?
Has Pankaj Mohan been buying or selling shares of Sonnet BioTherapeutics?
Over the course of the past ninety days, Pankaj Mohan has bought $81,752.00 in Sonnet BioTherapeutics stock. Most recently, on Monday, May 15th, Pankaj Mohan bought 371,600 shares of Sonnet BioTherapeutics stock. The stock was acquired at an average cost of $0.22 per share, with a total value of $81,752.00. Following the completion of the transaction, the chief executive officer now directly owns 553,331 shares of the company's stock, valued at $121,732.82. Learn More on Pankaj Mohan's trading history.
Who are Sonnet BioTherapeutics' active insiders?
Are insiders buying or selling shares of Sonnet BioTherapeutics?
In the last year, Sonnet BioTherapeutics insiders bought shares 3 times. They purchased a total of 419,855 shares worth more than $98,431.85. The most recent insider tranaction occured on May, 30th when Director Albert D Dyrness bought 23,255 shares worth more than $10,929.85. Insiders at Sonnet BioTherapeutics own 3.0% of the company.
Learn More about insider trades at Sonnet BioTherapeutics. Information on this page was last updated on 5/30/2023.
